Investments in associates (Tables)

12 Months Ended

Dec. 31, 2024

Investments in associates

Schedule of amounts recognised in the balance sheet and income statement

	2024	2023	2022
	$ million	$ million	$ million
Balance sheet	7	16	46
Income statement loss	(10)	(30)	(32)
Impairment of interest in associate	–	–	(109)

Summary of financial information for Bioventus, adjusted for differences with Group accounting policies

	2024	2023	2022
	$ million	$ million	$ million
Summarised statement of comprehensive income
Revenue	420	377	386
Attributable loss for the year	(34)	(152)	(129)
Group adjustments1	(2)	46	17
Total comprehensive loss	(36)	(106)	(112)
Group share of loss for the year at 27.13% (2023: 27.96%, 2022: 28.3%)	(10)	(30)	(32)

	2024	2023
	$ million	$ million
Summarised balance sheet
Non-current assets	471	562
Current assets	299	249
Non-current liabilities	(371)	(424)
Current liabilities	(211)	(160)
Net assets	188	227
Net equity attributable to owners	188	227
Group’s share of net assets at 27.13% (2023: 27.96%)	51	64
Group adjustments1,2	(45)	(48)
Group’s carrying amount of investment at 27.13% (2023: 27.96%)	6	16

1 Group adjustments include adjustments to align with Group policy.

2 Group adjustments also include impairment loss of share in associates of $109m from 2022.